RECIST 1.1, irRECIST 1.1, and mRECIST: How to Do
- 1.6k Downloads
Purpose of Review
This review aims to give a brief update how to do RECIST 1.1, irRECIST 1.1, and mRECIST.
The revised Response Evaluation Criteria in Solid Tumors (RECIST 1.1) are currently representing the most commonly used and validated response criteria for objective treatment monitoring of conventional chemotherapies in solid tumors. However, with the introduction of novel molecular drugs and local tumor therapies, such as selective transarterial chemoembolization (TACE) at hepatocellular carcinomas (HCC), limitations of the conventional RECIST 1.1 became obvious due to specific response pattern, which are not reflected. Thus, for a comprehensive evaluation of immunotherapeutic agents new immune-related RECIST (irRECIST 1.1) and of selective HCC treatment modified RECIST (mRECIST) criteria have been published.
RECIST 1.1 presents the most used response criteria for conventional chemotherapies in solid tumors. For specific evaluation of immunotherapeutic agents irRECIST 1.1 and of selective HCC treatment mRECIST have been established.
KeywordsResponse criteria RECIST 1.1 irRECIST 1.1 mRECIST
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 1.WHO. WHO handbook for reporting results of cancer treatment. World Health Organization Offset Publication No. 48, Geneva; 1979.Google Scholar
- 5.• Nishino M, Gargano M, Suda M, Ramaiya NH, Hodi FS. Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? J Immunother Cancer. 2014;2:17. doi: 10.1186/2051-1426-2-17. Original publication of irRECIST 1.1.
- 6.• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60. doi: 10.1055/s-0030-1247132. Original publication of mRECIST for HCC.
- 10.Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, et al. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013;19:3936–43. doi: 10.1158/1078-0432.CCR-13-0895.CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Hyun D, Shin SW, Cho SK, Park KB, Park HS, et al. Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma. Acta Radiol. 2015;56:1437–45. doi: 10.1177/0284185114560937.CrossRefPubMedGoogle Scholar
- 13.Sato Y, Watanabe H, Sone M, Onaya H, Sakamoto N, et al. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602. Ups J Med Sci. 2013;118:16–22. doi: 10.3109/03009734.2012.729104.CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Edeline J, Boucher E, Rolland Y, Vauléon E, Pracht M, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer. 2012;118:147–56. doi: 10.1002/cncr.26255.CrossRefPubMedGoogle Scholar
- 16.ACR. American College of Radiology - Liver Imaging Reporting and Data System version 2014. 2014. https://nrdr.acr.org/lirads/.